Children's Autism Metabolome Project



Status:Active, not recruiting
Conditions:Cognitive Studies, Neurology, Psychiatric, Psychiatric, Autism
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:Any
Updated:6/14/2018
Start Date:August 2015
End Date:August 2020

Use our guide to learn which trials are right for you!

Children's Autism Metabolome Project (CAMP): Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood

Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose
Autism Spectrum Disorder in Early Childhood.

The purpose of this study is to identify a metabolite signature in blood plasma and/or urine
using a panel of biomarker metabolites that differentiate children with autism spectrum
disorder (ASD) from children with delayed development (DD) and/or typical development (TD),
to develop an algorithm that maximizes sensitivity and specificity of the biomarker profile,
and to evaluate the algorithm as a diagnostic tool.

A secondary objective is to define metabolites capable of classifying subtypes of ASD that
may increase understanding of the metabolic basis of the condition, as well as inform on
personalized therapy.

The population targeted for this study includes children aged 18 months to 48 months,
diagnosed with ASD or DD using behavioral criteria, and TD children, identified as having no
indications of ASD or DD using behavioral criteria. The target size for each of the three
groups is 500 children, for a total of 1500 subjects. The targeted male:female ratio is 4:1
in all three groups. If the diagnostic biomarkers identified in the study do not perform well
in females during the biomarker discovery phase, the study may be expanded to recruit more
females to examine the possibility of a female-specific diagnostic test.

Subjects will be qualified for entry into the study and will be invited to participate. On
the first study day, subjects' parents will sign an informed consent form and will be asked
questions on the mother's pregnancy and of both parents' medical history. A complete medical
history, a physical examination, and information needed to obtain a diagnosis of ASD, DD, or
TD will be obtained on the study subject. If possible, a urine sample will be collected
during the visit. Up to four tubes of blood (<25 mLs total) will be drawn at the clinic
during the visit or within 14 days following this initial visit. An overnight fast is
required prior to the visit where blood will be taken from the subject. A subset of the
subjects will be asked to return to the clinic 30-60 days later to obtain a replicate
metabolic profile.

The study will be divided into a biomarker discovery/method development phase followed by a
validation phase of the analytical methods and algorithm that will be used in the clinical
test.

The first 375 subjects enrolled in each group (ASD, DD, TD) will be used in the
discovery/training set and the remaining 125 subjects will be held aside for use as a
validation set. The training set will be used for discovery of the biomarkers and development
of the analytical methods intended for the diagnostic test. The validation sample set will be
used to evaluate performance of the final clinical methods and algorithms.

Consent will also be sought from all subjects for follow-up contact up to 2 years following
enrollment to determine the accuracy of the original behavioral diagnosis. Subjects chosen
for follow-up will be identified based on the strength of the diagnosis from the behavioral
scores and physician assessments as well as the biomarker profiles observed in individuals.

Inclusion Criteria:

- Age of greater or equal to 18 months and less than or equal to 48 months

- Fulfills the definition of an autism spectrum disorder, developmentally delayed, or
typically developing child in the age range 18-48 months, as determined by a clinician
or certified practitioner of the appropriate tests and who is knowledgeable in the
field; and

- Has parental (or other legal guardian ) informed consent to participate.

Exclusion Criteria:

- Diagnosis with a chronic condition that could interfere with a diagnosis of ASD or DD,
(e.g.: a known history of Fragile X, Rett syndrome, Down syndrome, tuberous sclerosis,
trisomy 21, inborn errors of metabolism or other genetic disorder that includes some
symptoms of autism)

- Fetal alcohol syndrome, or other serious neurological disorder

- Other serious metabolic disorder, psychiatric disorder, or medical condition involving
the liver, kidney, pulmonary, cardiovascular or endocrine systems

- A second child within a family in which a sibling has already been enrolled.

- A child who has previously participated in the CAMP-01 study
We found this trial at
8
sites
Sacramento, California 95817
Phone: 916-703-0225
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Principal Investigator: Logan Wink, MD
Phone: 513-803-3582
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Phone: 614-722-2438
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Phone: 615-936-1598
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
 215-590-1000
Principal Investigator: Amanda Bennett-Palladino, MD
Phone: 267-426-5200
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1 Maguire Road
Lexington, Massachusetts 02142
Principal Investigator: Ann Neumeyer, MD
Phone: 781-860-1710
?
mi
from
Lexington, MA
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Phone: 501-364-4662
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Scottsdale, Arizona 85254
Phone: 480-443-0050
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials